Angiotensin-converting enzyme inhibitors prior to scleroderma renal crisis in systemic sclerosis: A systematic review and meta-analysis.
Anji XiongYuzi CaoQilang XiangZhuoyao SongYan ZhangShifeng ZhouYiying QiangHuini ChenZiyi HuHongxu CuiJie LuoYe WangYuan YangMin YangShiquan ShuaiPublished in: Journal of clinical pharmacy and therapeutics (2022)
We recommend against using ACEIs prior to SRC in SSc patients. The use of ACEIs prior to SRC is associated with a higher incidence of SRC and poorer prognosis, especially in patients with progressive SSc or SSc-related renal vasculopathy (SSc-related hypertension and proteinuria).
Keyphrases
- systemic sclerosis
- interstitial lung disease
- angiotensin converting enzyme
- tyrosine kinase
- end stage renal disease
- angiotensin ii
- blood pressure
- ejection fraction
- newly diagnosed
- multiple sclerosis
- chronic kidney disease
- public health
- prognostic factors
- risk factors
- patient reported outcomes
- patient reported
- arterial hypertension